NPY13-36 reduced brain damage and improved motor function when given during reperfusion in hypertensive rats after stroke, revealing a new blood vessel protection mechanism.
Novel vasoprotection discoveredFirst demonstration that NPY13-36 protects brain blood vessels (not just neurons) during stroke recovery in hypertensive animals
What the researchers found
NPY13-36 was injected directly into the brain during either the ischemic phase (while blood flow was blocked) or the reperfusion phase (when blood flow returned). The drug was effective when given during reperfusion, not during ischemia.
During reperfusion, NPY13-36 reduced infarct size (the dead brain area), improved gait, mobility, and sensorimotor function, and restored normal microcirculatory response to nitric oxide synthase blockade. The vasoprotective effect was a new discovery, meaning the drug protected the tiny blood vessels in the brain, not just the neurons.
Why it matters
Most stroke neuroprotection research uses healthy young animals, which poorly represents human stroke patients who typically have high blood pressure and other conditions. This study used hypertensive rats, making it more clinically relevant. The discovery of vasoprotection (blood vessel protection) in addition to neuroprotection is a new mechanism that could be important for stroke treatment.
The numbers in context
- Dose: 10 μg NPY13-36 in 6 μL saline, given into brain ventricles
- Ischemia duration: 90 minutes of middle cerebral artery occlusion
- Drug was effective during reperfusion but not during ischemia
- Reduced infarct area
- Improved gait, mobility, and sensorimotor scores
- Restored microvascular response to NO synthase blockade
How the study worked
Researchers used spontaneously hypertensive rats (SHR), which naturally develop high blood pressure. They blocked the middle cerebral artery for 90 minutes to cause stroke, then allowed blood to return. NPY13-36 (10 micrograms in 6 microliters saline) was injected into the brain ventricles during either ischemia or reperfusion. Brain blood flow was monitored with laser-Doppler. Outcomes included infarct size (TTC staining), behavioral tests, and microvascular responses.
Who was studied
Spontaneously hypertensive rats (SHR) with experimentally induced middle cerebral artery occlusion and reperfusion
What this study cannot tell us
This was tested in rats, not people. The drug was injected directly into the brain, which is not a practical delivery method for human patients. The sample size is not stated in the abstract. Spontaneously hypertensive rats, while better than healthy rats, still do not fully replicate human stroke. The drug had to be given very shortly after reperfusion, which may not be achievable clinically.
How to read the evidence
Rated preliminary: promising animal study in a clinically relevant model, but the drug was injected directly into the brain, which is not practical for human use.
When this study was published
Published in 2024. This is early-stage preclinical research contributing to the NPY neuroprotection field.
The bigger picture
Most stroke neuroprotection studies use healthy young animals, which poorly represents real stroke patients who typically have high blood pressure. Testing in hypertensive animals makes results more clinically relevant.
Questions still open
- Can NPY13-36 be delivered without brain injection?
- Would the drug work with a longer delay after reperfusion begins?
- Can the vasoprotective mechanism be targeted more specifically?
Common questions
What is NPY13-36?
Why use hypertensive rats?
Read the original research
Neuro- and vasoprotective potential of neuropeptide Y Y2 receptor agonist, NPY13-36, against transient focal cerebral ischemia in spontaneously hypertensive rats.
Neuroscience, 562, 10-23
Citation
Przykaza, Łukasz; Domin, Helena; Śmiałowska, Maria; Stanaszek, Luiza; Boguszewski, Paweł M; Kozniewska, Ewa. (2024). Neuro- and vasoprotective potential of neuropeptide Y Y2 receptor agonist, NPY13-36, against transient focal cerebral ischemia in spontaneously hypertensive rats.. Neuroscience, 562, 10-23. https://doi.org/10.1016/j.neuroscience.2024.10.035